World has suffered a lot due to Covid 19- Coronavirus. It
has impacted both personal and professional lives of many. Sad loss of life of
many individuals across the world.
Glenmark Pharmaceuticals has announced that they are
launching medicine FabiFlu in tablet form for the treatment of mild &
moderate coronavirus (COVID-19)
cases in India. Nearly 80% of all COVID-19 positive cases in India are under this category.
FabiFlu is India’s first oral antiviral drug for treatment of mild &
moderate COVID-19 patients, the company said.
The company had on Friday received approval from Indian drug
regulator for manufacturing and marketing of Favipiravir in oral form in India.
On Saturday the company said the drug would be available from the evening near
its factory areas and pan India in 7 to 10 days.
The drug will be available in strips containing 34 tables
priced at ₹3,500 which works out to be ₹103 per tablet. The prescribed dose is
18 tablets on the first day with 9 tablets of 200 mg each in morning and
evening. From second day onwards the patient needs to take 4 tablets each in
morning and day. The treatment can last upto 14 days. Patients in the age group
of 18 and 75 can have it.
God Bless everyone.
No comments:
Post a Comment